The Ordinary General Assembly of the Jerusalem Pharmaceutical Group held its annual meeting of shareholders, during which it approved the distribution of cash dividends of 15% of the original share value for the fiscal year ending on December 31, 2022.

The meeting, which was held at the group's main headquarters in the city of Al-Bireh, was attended by the Group's Chairman of the Board of Directors, Mr. Muhammad Al-Masrouji, members of the Board and a number of shareholders, in addition to a number of Gaza shareholders who attended via video conferencing technology (visual communication), and representatives of the Companies Controller, the Palestine Stock Exchange, and an auditor The accounts and legal advisor of the group and the general manager of the group, Mr. Rami Kotb, and members of the executive management.

Al-Masrouji welcomed the attendees and congratulated them on the advent of the holy month of Ramadan and on the occasion of the Islamic and Christian holidays, pointing out that the group's performance during the year 2022 was reassuring and better than its predecessors, despite all the obstacles.

The Chairman of the Board reviewed the most important achievements during the past year, noting that the Jerusalem Pharmaceutical Group achieved a net profit of $7 million, compared to $6.2 million for the year 2021, a growth of 13%.

He pointed out that a number of markets have been opened in Africa and Asia, and export operations have been carried out through factories in Palestine and Jordan, which will be the nucleus for increasing sales. He informed the shareholders that the group obtained the Swiss accreditation, which will enable the company to market its medicines in Switzerland, manufacture for Swiss companies, and manufacture Jerusalem medicines as well there.

Al-Masrouji explained that the company is working on a strategic plan for the coming years, during which it will double its sales and profits. Work has been done during the year 2022 to develop distinctive new varieties. As well as the development and establishment of production lines, where the investment in new items and development of production lines exceeded the amount of 3 million US dollars.